A Prospective, Open, Dose-escalation, Multi-center, Phase 1 Trial to Evaluate Tolerability and Safety of Intramuscularly Administered BD03, a DNA Vaccine for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient
Latest Information Update: 05 May 2020
At a glance
- Drugs SL-V10 (Primary)
- Indications Cytomegalovirus infections; Polyomavirus infections
- Focus Adverse reactions
- Sponsors SL VAXiGEN
Most Recent Events
- 10 Jul 2018 New trial record